SGMT
Sagimet Biosciences Inc

1,901
Loading...
Loading...
News
all
press releases
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?
Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·17d ago
News Placeholder
More News
News Placeholder
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·17d ago
News Placeholder
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?
Zacks·3mo ago
News Placeholder
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know
Zacks·3mo ago
News Placeholder
Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate
Many investors eagerly await further announcements at the conference, with some buying based on rumors of a significant update.
Stocktwits·8mo ago
News Placeholder
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily...
PR Newswire·10mo ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Sagimet Biosciences, Inc. Class A (SGMT)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Liquidia Technologies (LQDA Research Report) and Sagimet Biosciences, Inc. Class A...
TipRanks Financial Blog·1y ago
News Placeholder
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $41.50 Average PT from Analysts
Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has received an average rating of "Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. Six...
Ticker Report·1y ago
News Placeholder
Sagimet Biosciences CEO, President & Director Acquires 553% More Stock
Even if it's not a huge purchase, we think it was good to see that David Happel, the CEO, President & Director of...
Simply Wall St·1y ago
News Placeholder
Sagimet Biosciences (NASDAQ:SGMT) PT Lowered to $27.00 at The Goldman Sachs Group
Sagimet Biosciences (NASDAQ:SGMT Free Report) had its price objective cut by The Goldman Sachs Group from $37.00 to $27.00 in a report issued on Tuesday, Benzinga reports. They currently have...
Zolmax·1y ago

Latest SGMT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.